Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 5/20 | 0.52 |
| ▸ | KIT | P10721 | 2/20 | 0.52 |
| ▸ | FLT3 | P36888 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | JAK2 | O60674 | 6/20 | 0.47 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.45 |
| ▸ | JAK1 | P23458 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30633321 | 1.00 | KDR (0.52) | KDRKITFLT3NPC1RAB9A | |
| SCHEMBL30633358 | 0.88 | JAK2 (0.46) | KDRJAK2MAPK1JAK1MAPT | |
| SCHEMBL26686302 | 0.88 | JAK2 (0.46) | KDRJAK2MAPK1JAK1MAPT | |
| SCHEMBL26686141 | 0.87 | JAK2 (0.45) | JAK2MAPK1JAK1 | |
| SCHEMBL30633313 | 0.87 | JAK2 (0.45) | JAK2MAPK1JAK1 | |
| SCHEMBL30633312 | 0.87 | JAK2 (0.45) | JAK2MAPK10MAPK1JAK1 | |
| SCHEMBL26685861 | 0.85 | JAK2 (0.56) | KDRKITFLT3NPC1RAB9A | |
| SCHEMBL30633352 | 0.85 | JAK2 (0.56) | KDRKITFLT3NPC1RAB9A | |
| SCHEMBL30633362 | 0.84 | JAK2 (0.53) | KDRKITFLT3JAK2MAPK10 | |
| SCHEMBL26686340 | 0.82 | JAK2 (0.56) | KDRJAK2MAPK1JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304576-A1 | IKK INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2025-10-02 | — | — | US | claimed |
| EP-4522597-A1 | IKK INHIBITORS | Cancer Research Technology Limited (GB) | 2025-03-19 | — | — | EP | claimed |
| WO-2023218201-A1 | IKK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-11-16 | — | — | WO | claimed |
| US-20250304576-A1 | IKK INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2025-10-02 | — | — | US | disclosed |
| EP-4522597-A1 | IKK INHIBITORS | Cancer Research Technology Limited (GB) | 2025-03-19 | — | — | EP | disclosed |
| WO-2023218201-A1 | IKK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023218201-A1 | IKK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304576-A1 | IKK INHIBITORS | NFKBIA, IKBKE, IKBKB | KDR 2334/4885KIT 2180/4885FLT3 601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.